Nifty Pharma Outperforms Nifty-50 By 50% Since 2020: Emkay Global

Nifty Pharma has outperformed the Nifty-50 by 50% since the start of 2020, stretching Nifty Pharma's 1-yr forward P/E to 29x vs. 10-year avg. of 24x, Emkay Global has said in a report. "As Covid tailwinds recede, we expect outperformance to

from Tax Saving Investments | Tax Saving Tips & News | Income Tax India – Oneindia Money https://ift.tt/3isC3zw
via IFTTT